CAGR of 63% forecast for NASH market across the US and five EU countries, says analyst

In anticipation of new drug approvals in a therapy sector that has no current treatments available but many in the research pipeline, the market for non-alcoholic steatohepatitis (NASH) is expected to see rapid growth.

The market for NASH is set to expand at a compound annual growth rate (CAGR) of 63% across the USA and the five major European markets (5EU; France, Germany, Italy, Spain and the UK) to reach $18.3 billion by 2026, according to data and analytics company GlobalData.  An earlier report from the company put NASH product sales at $138.4 million in 2016.

GlobalData says that both the attractive market potential and the significant unmet needs for NASH, which has no FDA-approved products, stimulated mergers and acquisitions and strategic alliance deal activity between 2014 and 2016.